Pancreatic cancer specific binding peptide and preparation method and application thereof

CN122255229BActive Publication Date: 2026-08-28BEIJING BEISHENG BIOTECHNOLOGY CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202610423946.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-04-01
Publication Date
2026-08-28
Estimated Expiration
2046-04-01

AI Technical Summary

Technical Problem

[0005]尽管如此,目前国内外面向胰腺癌、特别是特异性靶向CLDN18.2的高亲和力多肽分子仍报道较少

Benefits of technology

[0017]与现有技术相比,本发明的有益效果主要在于:

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122255229B_ABST
    Figure CN122255229B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to a pancreatic cancer specific binding peptide and a preparation method and application thereof. The pancreatic cancer specific binding peptide is a chelator-mediated radionuclide labeled HFL2c peptide; the radionuclide includes an imaging radionuclide or a therapeutic radionuclide; and the amino acid sequence of the HFL2c peptide is shown in SEQ ID NO. 1. Test results show that the polypeptide can be targeted to combine with the extracellular region of CLDN18.2, and the radionuclide labeled HFL2c peptide prepared by using the polypeptide can be used for nuclide imaging, realizes precise positioning, quantitative monitoring and high-sensitivity in-vivo imaging of CLDN18.2 expression, and is suitable for early screening, diagnosis and treatment monitoring of pancreatic cancer. Meanwhile, the therapeutic radionuclide labeled HFL2c peptide prepared by using the polypeptide can inhibit the growth of pancreatic cancer tumors.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • CLDN18.2-targeting polypeptide, radionuclide-labeled targeting peptide and application of CLDN18.2-targeting polypeptide

    CN116925179A

  • Modified CAIX targeting cyclic peptide, nuclide marker and application of modified CAIX targeting cyclic peptide in tumor diagnosis and treatment

    CN120943901A